Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood



In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of EANO provides recommendations for the diagnosis, treatment and follow-up of adult patients with diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy — Not Officially WHO (cIMPACT-NOW). With regard to therapy, we formulated recommendations based on the results from the latest practice-changing clinical trials and also provide guidance for neuropathological and neuroradiological assessment. In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided. This document is intended to be a source of reference for professionals involved in the management of adult patients with diffuse gliomas, for patients and caregivers, and for health-care providers.


The classification of gliomas has undergone major changes through the revision of the fourth edition of the WHO Classification of Tumors of the Central Nervous System1 in 2016. Further refinements of the classification were subsequently proposed by the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy — Not Officially WHO (cIMPACT-NOW)2,3,4. These documents enable a diagnosis of glioblastoma to be made not only based on histology but also on the basis of several molecular markers and propose the discontinuation of the term ‘IDH-mutant glioblastoma’. To reflect these changes, the European Association of Neuro-Oncology (EANO) considered it necessary to update its guidelines for the management of adult patients with gliomas5 (Box 1). In the present evidence-based guidelines, we cover the prevention, early diagnosis and screening, integrated histomolecular diagnostics, therapy and follow-up monitoring of adult patients with diffuse gliomas. Aspects such as differential diagnosis, adverse effects of treatment, and supportive and palliative care are beyond the scope of this guideline document.


These evidence-based guidelines were formulated by a task force nominated by the EANO Executive Board following a proposal by the Chair of the EANO guidelines committee. This task force includes representatives of all the disciplines involved in the diagnosis and care of adults with glioma and reflects the multinational character of EANO. References were retrieved from the PubMed database using the search terms ‘glioma’, ‘anaplastic’, ‘astrocytoma’, ‘oligodendroglioma’, ‘glioblastoma’, ‘trial’, ‘clinical’, ‘surgery’, ‘radiotherapy’ and ‘chemotherapy’ between January 2011 and July 2020. Publications were also identified through searches of the authors’ own libraries. Only publications in English were reviewed. Data available only in abstract form were included in exceptional circumstances. The definitive reference list was generated based on relevance to the broad scope of these guidelines. The consensus recommendations were achieved through repeated circulation of manuscript drafts and telephone conferences involving members of the task force to discuss the most controversial areas. The key recommendations for the diagnosis and management of diffuse gliomas of adulthood, with their class of evidence (C) and level of recommendation (L)6 are reported at the end of each corresponding paragraph.

Epidemiology and prevention

The annual incidence of gliomas is approximately of six cases per 100,000 individuals worldwide. Men are 1.6-fold more likely to be diagnosed with gliomas than women7. While the vast majority of cases are sporadic, certain familial tumour syndromes are associated with gliomagenesis, including neurofibromatosis type I, tuberous sclerosis, Turcot syndrome, Li–Fraumeni syndrome and Lynch syndrome. Screening with neuroimaging is limited to patients with such syndromes at the initial diagnostic work-up8. Repeat neuroimaging is not indicated unless new neurological symptoms and signs, such a seizures, aphasia, hemiparesis or sensory deficits, develop that suggest an intracranial lesion. The counselling and screening of asymptomatic relatives of patients with glioma who are found to be carriers of germline mutations associated with gliomagenesis should be conducted with caution and in cooperation with clinical geneticists. No known measures to prevent the development of gliomas exist.

History and clinical examination

The evolution of neurological symptoms and signs enables the estimation of the growth dynamics of gliomas: tumours that cause symptoms only weeks before diagnosis are usually fast growing whereas those that cause symptoms for years before being diagnosed are usually slow growing. In most individuals, the symptoms and signs reported the year before diagnosis are non-specific (for example, fatigue or headache)9,10,11. A discussion of the patient’s history might reveal familial risk or rare exogenous risk factors (such as exposure to radiation) associated with the development of brain tumours. Information from relatives might be required to obtain a reliable history. Firm recommendations on when and how to involve family members and caregivers and how to assess the medical decision-making capacity in patients with brain tumours remain to be developed12.

Characteristic modes of clinical presentation include new-onset epilepsy, focal deficits (such as pareses or sensory disturbances), neurocognitive impairment, and symptoms and signs of increased intracranial pressure. The physical examination of patients with brain tumours focuses on the detection of systemic cancer to differentiate primary brain tumours from brain metastases and contraindications for neurosurgical procedures. The Neurological Assessment in Neuro-Oncology (NANO) scale can be used to document some of the results of the neurological examination13. Neurocognitive assessment using a standardized test battery14, beyond documenting performance status and performing a Mini Mental State Examination (MMSE)15 or a Montreal Cognitive Assessment (MoCA)16, has become increasingly common. Despite its limitations, the MMSE is widely used as a screening instrument to detect neurocognitive impairment and remains freely available for individual use.


  • Karnofsky performance score (KPS), neurological function, age, and individual risks and benefits should be considered for clinical decision-making. C: IV; L: A.

  • Screening and prevention have no major role for patients with gliomas. C: IV; L: C.

  • Patients with relevant germline variants or suspected hereditary cancer syndromes should receive genetic counselling and might subsequently be referred for molecular genetic testing. C: IV; L: C.

Preoperative diagnostics

Brain MRI, including T2-weighted, T2-weighted fluid-attenuated inversion recovery (FLAIR) sequences and 3D T1-weighted sequences before and after application of a gadolinium-based contrast agent, is the diagnostic gold standard to detect a brain tumour17. Perfusion MRI and amino acid PET can help to define metabolic hotspots for specific tumour tissue sampling, a technique that can be particularly useful if biopsy rather than open resection is considered18. Electroencephalography can be helpful in the monitoring of tumour-associated epilepsy and in determining the cause of altered consciousness. A large number of studies has shown that cell-free tumour DNA can be detected in the plasma and cerebrospinal fluid of patients with glioma; however, the benefits of using liquid biopsies for the screening, early detection or preoperative work-up of patients with gliomas remain to be proven19.


  • The first choice of diagnostic imaging modality is MRI without and with the administration of a gadolinium-based contrast agent. C: IV; L: B.

  • Pseudoprogression should be considered in patients with an increase of abnormalities on neuroimaging in the first months after local therapeutic interventions, including radiotherapy, and after experimental local treatments. C: IV; L: B.

Preoperative management

Patient management before surgery should follow written local standard operating procedures and involve multidisciplinary discussions, ideally by a dedicated multidisciplinary tumour board including neuroradiologists and neuropathologists as well as neurosurgeons, radiation oncologists and dedicated neuro-oncologists from neurology or medical oncology services and from paediatric oncology as needed. Prior to surgery, corticosteroids can be administered to decrease symptomatic tumour-associated oedema unless primary cerebral lymphoma or inflammatory lesions are suspected. Alternative pharmacological measures, such as osmotic agents, are rarely necessary. Patients who have suffered epileptic seizures should receive anticonvulsant drugs preoperatively. Primary prophylaxis does not reduce the risk of a first seizure in patients with glioma without a history of seizures20.

Tissue acquisition

Treatment decisions in patients with glioma are made based on tissue diagnosis, including the assessment of molecular markers relevant for diagnosis; therefore, upfront surgery is commonly performed with both diagnostic and therapeutic intent. The surgical management of patients with glioma should take place in high-volume specialist centres where large numbers of patients are referred to specialist neurosurgeons21. A decision for palliative care management without histological diagnosis should be avoided unless the risk of adverse outcomes from biopsy sampling is considered too high or if the prognosis is likely to be very unfavourable, for example, in patients with a high burden of comorbidities, large lesions with a typical radiological appearance of glioblastoma and rapid neurological deterioration. Definitive histological diagnoses aid in the counselling of patients and caregivers, even when no further tumour-specific therapy is recommended.

When microsurgical resection is not safely feasible (for example, owing to the tumour location or the impaired clinical condition of the patient), a stereotactic biopsy should be performed. Frame-based or frame-less stereotactic biopsy sampling is associated with a low risk of morbidity and a high level of diagnostic accuracy22,23. Serial samples of the tumour mass should be acquired along the trajectory of the biopsy needle in order to avoid sampling bias. Experienced teams can derive adequate tissue specimens for molecular profiling using these techniques22. IDH mutations and 1p/19q codeletion as disease-defining markers as well as MGMT promoter methylation24 are homogeneously present within tumours and, thus, the risk of sampling error for these markers is low. However, for additional markers of interest for which homogeneity has not been shown, sampling has to include different areas of the tumour; this principle applies for both stereotactic and open procedures. Intraoperative use of the fluorescent dye 5-aminolevulinic acid can be helpful to ensure adequate sampling during stereotactic biopsies25. Some centres prefer open biopsy approaches to ensure that sufficient tissue is obtained for any molecular studies that might be required to guide clinical decision-making.


  • Clinical decision-making without obtaining a tissue diagnosis should be considered only in very exceptional situations. C: IV; L: not applicable.

Integrated histomolecular classification

Intraoperative assessment of cytological specimens or frozen sections ensures that sufficient tumour tissue is obtained to establish a diagnosis. Tumour tissue is formalin fixed and embedded in paraffin for histological and immunohistochemical staining as well as for molecular genetic and cytogenetic studies. If possible, some tumour tissue should be cryopreserved for molecular assessments that require high-quality DNA and RNA samples. The diagnostic process should follow the WHO classification of 2016 (ref.1) and the subsequent recommendations from cIMPACT-NOW2,3,4. Accordingly, glioma classification integrates histological tumour typing and grading as well as analyses of molecular markers (Fig. 1). The term ‘not otherwise specified’ was introduced to refer to gliomas that were not tested for markers relevant to the diagnosis of specific subtypes or for which testing was inconclusive1.

Fig. 1: Diagnostic algorithm for the integrated classification of the major diffuse gliomas in adults.
figure 1

Tissue specimens obtained through biopsy sampling in patients with diffuse gliomas are routinely assessed by immunohistochemistry for the presence of R132H-mutant IDH1 and loss of nuclear ATRX. In patients aged >55 years with a histologically typical glioblastoma, without a pre-existing lower grade glioma, with a non-midline tumour location and with retained nuclear ATRX expression, immunohistochemical negativity for IDH1 R132H suffices for the classification as IDH-wild-type glioblastoma1. In all other instances of diffuse gliomas, a lack of IDH1 R132H immunopositivity should be followed by IDH1 and IDH2 DNA sequencing to detect or exclude the presence of non-canonical mutations. IDH-wild-type diffuse astrocytic gliomas without microvascular proliferation or necrosis should be tested for EGFR amplification, TERT promoter mutation and a +7/–10 cytogenetic signature as molecular characteristics of IDH-wild-type glioblastomas2. In addition, the presence of histone H3.3 G34R/V mutations should be assessed by immunohistochemistry or DNA sequencing to identify H3.3 G34-mutant diffuse hemispheric gliomas, in particular in young patients with IDH-wild-type gliomas (such as those <50 years of age with nuclear ATRX loss in tumour cells). Diffuse gliomas of the thalamus, brainstem or spinal cord should be evaluated for histone H3 K27M mutations and loss of nuclear K27-trimethylated histone H3 (H3K27me3) to identify H3 K27M-mutant diffuse midline gliomas. The presence and absence of the diagnostically most relevant molecular alterations for each tumour type are highlighted with red and green boxes. MVP, microvascular proliferation.

On the basis of the 2016 WHO classification and cIMPACT-NOW recommendations, the following molecular biomarkers are central to categorizing diffuse gliomas in adults: IDH mutation, 1p/19q co-deletion, histone H3 K27M mutation, histone H3.3 G34R/V mutation, TERT promoter mutation, EGFR gene amplification, chromosome 7 gain combined with chromosome 10 loss (the +7/–10 signature), and homozygous deletions on 9p21 involving the CDKN2A and CDKN2B gene loci (CDKN2A/B homozygous deletion) (Table 1). Missense mutations in codon 132 of IDH1 or codon 172 of IDH2 are the defining molecular feature of IDH-mutant astrocytomas and are associated with the glioma CpG island methylator phenotype (G-CIMP). Diffuse gliomas corresponding histologically to WHO grade 2 or 3 that are immunohistochemically negative for IDH1 R132H should be sequenced for less common IDH1 and for IDH2 mutations. IDH-mutant astrocytomas usually also have loss of nuclear expression of ATRX and mutations in TP53 but, by definition, lack 1p/19q codeletion1. Indeed, the detection of nuclear ATRX loss in an IDH-mutant glioma is sufficient for the diagnosis of an astrocytic lineage tumour without the need for 1p/19q codeletion analysis. By contrast, retained nuclear ATRX positivity in an IDH-mutant glioma should prompt analysis for 1p/19q codeletion in order to distinguish IDH-mutant astrocytoma from IDH-mutant and 1p/19q-codeleted oligodendroglioma. ATRX immunohistochemistry is not necessary if IDH mutation and 1p/19q codeletion status are captured within one more extensive molecular marker panel assay. IDH-mutant astrocytomas are now stratified into three WHO grades: astrocytoma, IDH-mutant, WHO grade 2; astrocytoma, IDH-mutant, WHO grade 3 (instead of anaplastic astrocytoma, IDH-mutant, WHO grade 3); and astrocytoma, IDH-mutant, WHO grade 4 (replacing the former term ‘glioblastoma, IDH-mutant, WHO grade 4’)3. The term ‘glioblastoma’ is no longer used to refer to IDH-mutant astrocytic gliomas because these tumours are biologically distinct from the much more common IDH-wild-type glioblastomas, although their histological appearance is similar3. In addition to the established histological features, such as the presence of necrosis and/or microvascular proliferation, homozygous CDKN2A/B deletion is indicative of a poor prognosis26 and is a marker of WHO grade 4 IDH-mutant astrocytomas3. As the diagnostic term ‘astrocytoma, IDH-mutant’ can be associated with different tumour grades and the roman numerals II and III are easily confused, cIMPACT-NOW recommended the use of Arabic numerals for the WHO-based grading of these tumours3. In line with the sixth update of the cIMPACT-NOW recommendations4, in these evidence-based guidelines we use Arabic numerals for WHO grades.

Table 1 Molecular markers for the diagnosis and management of gliomas

Special attention should be given to diffuse astrocytomas in the brainstem or cerebellum with histologies corresponding to WHO grades 2, 3 and 4. Among infratentorial astrocytomas, the frequency of non-canonical IDH mutations is ~80%, in contrast with <10% in those of the supratentorial compartment27,28. Infratentorial diffuse gliomas therefore tend to be classified incorrectly if examined by IDH1 R132H immunohistochemistry only; accordingly, DNA sequencing for rare mutations in IDH1 and IDH2 is required. In addition, infratentorial IDH-mutant astrocytomas have a loss of nuclear ATRX expression as well as MGMT promoter methylation in only ~50% of patients27,28.

Oligodendroglial tumours are defined as IDH-mutant gliomas that also harbour 1p/19q codeletion1 and are stratified into WHO grade 2 or 3 tumours based on the absence or presence of histological features of anaplasia. The role of molecular alterations in the grading of these tumours has not been defined. However, similar to IDH-mutant diffuse astrocytomas, the homozygous deletion of CDKN2A at 9p21 has been associated with shorter survival durations29. Oligoastrocytomas lack characteristic genetic profiles and are no longer considered as a distinct glioma subtype.

Astrocytic gliomas with a wild-type IDH and histone H3 status and with necrosis and/or microvascular proliferation are classified as IDH-wild-type, WHO grade 4 glioblastomas1. In the absence of necrosis or microvascular proliferation, such tumours should be evaluated for glioblastoma-associated genetic alterations, in particular EGFR gene amplifications, TERT promoter mutations and/or the +7/–10 signature2. If one or more of these alterations is detected, these tumours are classified as IDH-wild-type glioblastomas given their association with a poor prognosis, even in the absence of necrosis and microvascular proliferation1,30. IDH-wild-type diffuse astrocytomas without any of these alterations, which cannot be assigned to other entities (for example, on the basis of DNA methylation profiling) are more often seen in paediatric, adolescent or young adult patients and constitute rare glioma variants that require further molecular assessment31.

H3 K27M-mutant, WHO grade 4 diffuse midline gliomas are defined as a diffuse glioma located in midline structures, such as the thalamus, pons, brainstem and spinal cord, and carrying a lysine-to-methionine mutation at amino acid 27 of histone H3.3 (encoded by H3F3A) or histone H3.1 (encoded by HIST1H3B and HIST1H3C)1. H3 K27M-mutant diffuse midline gliomas are typically positive for nuclear immunostaining of H3 K27M with the corresponding loss of nuclear staining for K27-trimethylated histone H3 (H3K27me3), which together serve as immunohistochemical markers of this tumour type. H3.3 G34-mutant, WHO grade 4 diffuse hemispheric glioma has been proposed as a new subtype of malignant glioma, characterized by missense mutations affecting codon 34 of H3F3A4,31.

MGMT promoter methylation has limited diagnostic value but can guide treatment decisions on the use of chemotherapy with alkylating agents for patients with glioblastoma or other IDH-wild-type gliomas32. As outlined below, MGMT promoter methylation enables the prediction of benefit from alkylating agents in patients with these tumours. MGMT promoter methylation status should be tested using methylation-specific PCR, pyrosequencing or methylation arrays (such as the MGMT-STP27 model)33. However, challenges remain, including: (1) establishing reliable MGMT promoter methylation status assays that can be used with high interlaboratory agreement, and (2) estimating the effect of limited MGMT promoter methylation, an intermediate state between the non-methylated and methylated phenotypes, on outcomes33. Immunocytochemistry is not an adequate method to determine the MGMT promoter methylation status34.

Next-generation sequencing-based gene panels could enable the assessment of all or most genetic and chromosomal aberrations relevant for diagnosis using a single assay35,36. In addition, array-based DNA methylation profiling has emerged as a powerful novel diagnostic method that is independent of histology and useful in the routine diagnostic work-up37. Moreover, RNA sequencing-based approaches present a promising approach for the detection of oncogenic gene fusions with diagnostic and/or predictive value that can be found in rare subsets of diffuse gliomas, mainly IDH-wild-type glioblastomas38,39. Overall, molecular diagnostic algorithms for patients with glioma (Fig. 1) should be standardized and should not result in delays in the administration of radiotherapy or tumour-specific pharmacotherapy.


  • Glioma classification should follow the most recent WHO Classification of Tumors of the Central Nervous System1, complemented by cIMPACT-NOW updates2,3,4. C: IV; L: B.

  • Immunohistochemistry for mutant IDH1 R132H protein and nuclear expression of ATRX should be performed routinely in the diagnostic assessment of diffuse gliomas. C: IV; L: B.

  • If immunohistochemistry for IDH1 R132H is negative, sequencing of IDH1 codon 132 and IDH2 codon 172 should be conducted in all WHO grade 2 and 3 diffuse astrocytic and oligodendroglial gliomas as well as in all glioblastomas of patients aged <55 years to enable integrated diagnoses according to the WHO classification and to guide treatment decisions. C: IV; L: B.

  • 1p/19q codeletion status should be determined in all IDH-mutant gliomas with retained nuclear expression of ATRX. C: II; L: B.

  • MGMT promoter methylation status should be determined in glioblastoma, notably in elderly or frail patients, to aid in decision-making for the use of temozolomide. C: I; L: B.

  • CDKN2A/B homozygous deletions should be explored in IDH-mutant astrocytomas. C: IV; L: B.

  • Combined chromosome 7 gain and chromosome 10 loss (+7/–10 signature), EGFR amplification and TERT promoter mutation should be tested in IDH-wild-type diffuse gliomas lacking microvascular proliferation and necrosis as histological features of WHO grade 4 to allow for a diagnosis of IDH-wild-type glioblastoma. C: IV; L: B.

  • Assessment of H3 K27M status should be done in diffuse gliomas involving the midline. C: IV; L: B.

  • BRAFV600 mutations might be assessed in IDH-wild-type diffuse gliomas. C: IV; L: C.

Therapy — general recommendations

Prognostic factors

Younger age and better performance status at diagnosis are major therapy-independent prognostic factors associated with favourable outcomes in adults with glioma7. Furthermore, molecular genetic factors, notably 1p/19q codeletion and IDH mutation status, had a strong prognostic value in the classification of gliomas in the past but, since 2016, have become disease-defining features and are therefore no longer prognostic within a given disease subtype. As a result, MGMT promoter methylation status has become the single most important prognostic factor in an era in which the vast majority of adults with glioma are treated with alkylating agent-based chemotherapy.

Surgical therapy

The therapeutic goal of surgery is to remove as much tumour tissue as safely feasible using microsurgical techniques, without compromising neurological function. Several tools, including surgical navigation systems housing functional MRI or diffusion tensor imaging datasets and intraoperative MRI, ultrasonography, functional monitoring and fluorescence-based visualization of tumour tissue with 5-aminolevulinic acid, help in reducing postoperative residual tumour volumes while keeping the risk of new neurological deficits low40. The use of evoked potentials, electromyography or brain mapping in awake patients under local anaesthesia to monitor and preserve language and cognition facilitates resections in eloquent areas41. Preventing new permanent neurological deficits that might jeopardize independence, reduce quality of life (QOL) and increase the risk of additional complications that might, in turn, delay or preclude further therapy is more important than the extent of resection because diffuse gliomas are not cured by surgery. Neurological deficits that occur because of surgery can sometimes be predicted preoperatively. In exceptional situations, anticipated minor deficits (such as quadrantanopia) might be deemed acceptable but only after a thorough process of shared decision-making42. Patients and their caregivers should also be informed that neurosurgery is always associated with some unpredictable risks. Postoperative deficits owing to emerging surgical complications are a negative prognostic factor that can interfere with further treatment and health-related QOL is of high priority to patients and their caregivers43. The extent of resection should be assessed within 24–48 hours of surgery through MRI (or CT if MRI is not possible), without and with contrast; MRI should include diffusion-weighted sequences to enable the detection of perioperative ischaemia44.

The role of the extent of resection and residual tumour volume as prognostic factors remains controversial within the neuro-oncology community because randomized controlled trials (RCTs) addressing this question are very difficult to perform, and almost no such trials exist. A lesser extent of resection and larger post-surgical residual tumour volumes are negative prognostic factors across gliomas of all grades and subtypes45,46. These observations have resulted in the multitude of technical developments to maximize the extent of resection summarized above. Nevertheless, whether and why the extent of resection truly matters remain controversial questions. First, rather than the percentage of extent of resection, clinicians might need to consider the absolute volume of remaining tumour tissue, including both enhancing and non-enhancing tumour tissue45,46,47. Second, early (<3 weeks) as opposed to later (3–5 weeks) initiation of postsurgical radiotherapy does not correlate with improved overall survival (OS)48. This finding is unexpected because one might predict that a longer time interval between surgery and start of radiotherapy would favour regrowth of the tumour and thus confer a survival disadvantage47. Third, evidence indicates that resectable tumours have a different biology that is overall less malignant than that of non-resectable tumours, which challenges the causal relationship between extent of surgery and survival. For example, in a prospective evaluation of the effect of surgical resection on survival after controlling for IDH status, the rate of gross total resection was higher in patients with IDH-mutant tumours than in those with IDH-wild-type tumours49. Indeed, retrospective data indicate that biopsy is more often the type of first surgery in patients with IDH-wild-type tumours than in patients with IDH-mutant tumours47. Attributing the longer survival durations associated with IDH-mutant versus IDH-wild-type tumours to the rate of gross total resection would therefore probably not be the correct conclusion. With these considerations, we do not intend to discourage efforts to achieve gross total resection but rather to acknowledge the limitations of data from retrospective uncontrolled studies.


  • The extent of resection is a prognostic factor and thus, efforts at obtaining complete resections are justified across all glioma entities. C: IV; L: B.

  • In the current surgical approach to gliomas, the prevention of new permanent neurological deficits has higher priority than the extent of resection. C: IV; L: C.


The goal of radiotherapy is to improve local control without inducing neurotoxicity. Indeed, radiotherapy delayed neurological deterioration and increased survival in several early clinical trials conducted in the past century50,51. The timing, dosing and scheduling of radiotherapy are determined by the disease subtype and prognostic factors, including age, KPS and residual tumour volume. Radiotherapy should start within 3–5 weeks after surgery48 and is commonly administered at 50–60 Gy in 1.8–2 Gy daily fractions. No evidence suggests additional benefit from high-dose versus low-dose radiation in patients with WHO grade 2 gliomas52 and, for those with higher WHO grade tumours, no data from randomized studies support the use of doses >60 Gy (ref.53). Hypofractionated radiotherapy with a higher dose per fraction and a lower total dose (for example, 15 × 2.67 Gy) is appropriate in older patients (>65–70 years of age) and in those with a poor prognosis (typically defined by a KPS of <70)54.

The area of the surgical bed plus the residual tumour area identified on T1-weighted, T2-weighted and FLAIR MRI sequences is defined as the gross tumour volume. To account for microscopic invasion, a margin of 1.0–2.0 cm is added to create the clinical target volume, which is generally modified to include abnormalities visualized on the basis of T2-weighted or FLAIR signals (for example, oedema) and constrained to anatomical barriers such as ventricles, tentorium and falx. Finally, another margin, usually of 0.3–0.5 cm, is added to enable for uncertainties in patient set-up and treatment delivery, generating the planning target volume55. The use of amino acid PET using tracers such as [11C-methyl]-l-methionine or O-(2-[18F]-fluoroethyl)-l-tyrosine to improve target delineation for radiotherapy has been evaluated in clinical trials but is not currently part of standard practice18. Structures at higher risk of toxicity from radiotherapy, including the optic nerves, optic chiasm, retinae, lenses, brainstem, pituitary, cochleae and hippocampi, should be delineated. Modern, highly conformal radiation techniques, including intensity-modulated radiotherapy for newly diagnosed tumours and stereotactic radiotherapy and radiosurgery for recurrent tumours, could provide superior target coverage and sparing of non-malignant brain tissue. Proton or heavy ion radiotherapy might be options to consider for patients with tumours close to brain regions at risk or in those with a favourable prognosis in order to avoid delayed toxicities, but RCTs are required to determine the tolerability, safety and efficacy of these approaches compared with standard radiotherapy56,57. Accurate patient positioning is required for all highly conformal approaches and is achieved with reproducible immobilization and digital imaging during treatment. Interstitial brachytherapy approaches have been investigated over many years as an alternative to external beam treatment but have not yet been shown to have an application in routine practice58. An MRI scan scheduled 3–4 weeks after completion of radiotherapy provides a new baseline to monitor the further course of disease.


Haematology, hepatic and renal laboratory values within the normal physiological ranges and exclusion of major lung or heart disease or infection are required prior to and during most pharmacological treatments for patients with glioma. Most patients with glioma receive chemotherapy with alkylating agents at some point in their disease course. Temozolomide, an oral DNA alkylating agent that penetrates the blood–brain barrier, is the most commonly used drug in glioma treatment. This agent has a favourable safety profile, with myelosuppression, notably thrombocytopenia, as its main dose-limiting toxicity59. Hepatic function also needs to be monitored regularly in patients receiving temozolomide. In contrast to temozolomide, alkylating agents from the nitrosourea class, such as lomustine, carmustine, nimustine or fotemustine, cause delayed (4–6 weeks) rather than early (2–3 weeks) and more often cumulative leukopenia and thrombocytopenia. Notably, the latter can necessitate treatment interruptions, dose reductions or even discontinuation and consideration of alternative treatments. Pulmonary fibrosis has been observed mainly with carmustine and is rare with lomustine60. Lomustine is often combined with procarbazine and vincristine in a regimen referred to as PCV. Carmustine wafers implanted into the post-surgical cavity provided a modest OS benefit in patients with newly diagnosed WHO grade 3 or 4 gliomas or recurrent glioblastoma61,62; however, in the pivotal trial of this approach, patient outcomes were not statistically significantly different after patients with WHO grade 3 tumours (the majority of which are now known to be IDH-mutant) were excluded from the survival analysis. The benefit from alkylating agent chemotherapy demonstrated in various RCTs (described later) has to be weighed against the potential long-term toxicities and the risk of inducing a hypermutator phenotype that is associated with a more malignant phenotype, in particular in patients with IDH-mutant gliomas, who have a longer life expectancy63,64.

Bevacizumab, an anti-VEGF antibody, is approved for the treatment of recurrent glioblastoma in the USA, Canada, Switzerland and several other countries outside the European Union, but no OS benefit has been demonstrated from its use65,66,67. Patients with glioma receiving systemic therapy should carry a documentation of treatment, including laboratory results and information on complications and contraindications, to facilitate follow-up and to provide information to physicians in an emergency setting. Clinical centres managing patients with glioma should generate standard operating procedures and instructions for standardized application of chemotherapy as well as for the management of adverse events and complications from treatment.

Monitoring and follow-up assessments

Watch-and-wait strategies without histological verification carry the risk of underestimating the grade of malignancy when determined using only neuroimaging and thus require initial intervals of only 2–3 months between scans. In addition to clinical examination, MRI is the standard diagnostic measure for the evaluation of disease status or treatment response, using Response Assessment in Neuro-Oncology (RANO) criteria68,69,70 and identical MRI protocols according to published recommendations71. After the completion of therapy, an initial interval between scans of 2–6 months is common practice for most patients depending on the disease histology but longer intervals might be appropriate in cases of durable disease control and more benign tumours. Careful consideration of not only the most recent MRI scan but also of the complete disease trajectory is required, specifically in patients with slow-growing untreated lesions72. Conversely, in the event of suspected disease progression, short-term control MRI within 4–8 weeks might be reasonable to confirm progression. Pseudoprogression (typically after chemoradiotherapy or immunotherapy) and pseudoresponse (for example, after anti-angiogenic therapy) are most likely to occur during the first 3 months of treatment but can also occur later70. Particular attention is needed when interpreting scans during this period; in case of doubt, rescanning after shorter intervals (4–8 weeks) is a pragmatic approach. Perfusion MRI and amino acid PET might help to distinguish pseudoprogression from true disease progression73. Biopsy sampling is not always informative because viable tumour cells are regularly detected but their presence does not rule out pseudoprogression.

As for other non-curable diseases, patients with gliomas should be offered counselling by specialized psychologists or nurses and palliative care specialists. The need for occupational, speech and physical therapy as well as for counselling for social support should be assessed74.

Therapy — specific recommendations

IDH-mutant and 1p/19q-codeleted oligodendroglioma, WHO grade 2

Surgery is the primary treatment modality for patients with gliomas of this subtype. Following surgery, watch-and-wait strategies are justified in those with gross total resection and potentially also in younger patients (<40 years of age) with incomplete resection if the tumour has not yet caused neurological deficits beyond symptomatic epilepsy. If further treatment beyond surgery is deemed necessary, the standard of care is radiotherapy followed by PCV75. The use of chemotherapy alone remains investigational but might be an option to reduce the risk of late cognitive deficits in patients with large tumours owing to the favourable outcomes of this patient population relative to those with other subtypes76,77. The choice of treatment at recurrence depends on the initial treatment (Table 2, Fig. 2).

Table 2 Key treatment recommendations for adult patients with common diffuse gliomas
Fig. 2: Clinical pathway for IDH-mutant gliomas.
figure 2

KPS, Karnofsky performance status; PCV, procarbazine, lomustine and vincristine.

IDH-mutant and 1p/19q-codeleted oligodendroglioma, WHO grade 3

In this subtype, the extent of resection is a prognostic factor78. The distinction of two grades (2 and 3) of IDH-mutant, 1p/19q-codeleted gliomas remains controversial and, accordingly, watch-and-wait strategies after complete resection can also be considered for younger patients (<40 years of age) with WHO grade 3 tumours, specifically for those without homozygous CDKN2A/B deletion, although only after gross total resection and in the absence of neurological deficits. Two large RCTs showed that the addition of PCV, either prior to or after radiotherapy, in the first-line of treatment approximately doubled the OS79,80. Although these results stem from analyses of small cohorts of patients, both studies showed similar results, thus validating the findings and defining the current standard of care. Important open questions include: (1) whether neurocognitive function and health-related QOL are preserved in long-term survivors treated with radiotherapy and PCV81, and (2) whether the same improvement in OS could be achieved with temozolomide-based chemoradiotherapy. Long-term results from the NOA-04 trial showed that chemotherapy alone (either PCV or temozolomide) is not superior to radiotherapy alone in any molecular subgroup of anaplastic glioma, thus indicating that alkylating agent-based chemotherapy alone is unlikely to result in the same outcome as radiotherapy followed by PCV82. The modified CODEL trial83 will address whether temozolomide-based chemoradiotherapy is similarly effective as radiotherapy followed by PCV.

The choice of treatment at progression is influenced by the choice of and response to first-line therapy (Fig. 2). Second surgery should always be considered. If neither radiotherapy nor alkylating agents are options owing to ineffectiveness or intolerance in the first-line setting, bevacizumab can be used for symptom control; however, the antitumour efficacy of bevacizumab is unknown and no evidence supports its combination with cytotoxic agents in this setting.

IDH-mutant astrocytoma, WHO grade 2

Most WHO grade 2 astrocytomas harbour IDH mutations. Gemistocytic astrocytoma is a distinct variant of IDH-mutant astrocytoma, WHO grade 2. Maximal surgical resection, if safely feasible, is the best initial therapeutic approach84. Watch-and-wait strategies without the establishment of an integrated diagnosis should only be considered in exceptional situations, even for patients with incidentally discovered lesions. Younger patients (pragmatic cut-off ~40–45 years of age) who are asymptomatic or with seizures only, can be managed through observation alone after gross total resection. Involved-field radiotherapy (50 Gy in 1.8 Gy fractions) should be considered for patients with incomplete resection and/or for patients aged >40 years. Early radiotherapy (as opposed to radiotherapy after disease progression) has been shown to prolong progression-free survival (PFS) but not OS85. The use of chemotherapy alone as frontline therapy remains investigational but might be an option if radiotherapy is not feasible, for example, in patients with large tumours. However, the PFS is probably shorter with temozolomide than with radiotherapy in patients with IDH-mutant, grade 2 diffuse astrocytomas86. The RTOG 9802 trial reported a major prolongation of OS with the addition of PCV polychemotherapy to radiotherapy (54 Gy), from 7.8 years to 13.3 years in patients with high-risk WHO grade 2 gliomas who were 18–39 years of age and had undergone a subtotal resection or biopsy or in those aged ≥40 years75. This benefit was reported across histological subgroups and, although cohort sizes were small, benefit was observed in patients with either IDH-mutant astrocytomas or oligodendrogliomas but not in those with IDH-wild-type tumours87. Thus, radiotherapy followed by PCV constitutes the standard of care for patients with WHO grade 2 IDH-mutant astrocytomas deemed to require post-surgical treatment.

Treatment at progression depends on neurological status, patterns of progression and first-line therapy (Fig. 2). Second surgery should always be considered, usually followed by radiotherapy in patients who had not previously received irradiation, or by alkylating agent-based chemotherapy. Temozolomide is often preferred over PCV in this setting owing to its favourable safety profile and ease of administration.

IDH-mutant astrocytoma, WHO grade 3

The standard of care for patients with this disease subtype is maximal surgical resection or biopsy followed by radiotherapy at 60 Gy in 1.8–2 Gy fractions (Table 1). This approach was established largely based on trials in which subgroups of patients with WHO grade 3 tumours were pooled with those with glioblastomas. The NOA-04 trial showed similar PFS and OS with PCV or temozolomide alone versus radiotherapy alone78,82. The EORTC 26053 trial (CATNON) of radiotherapy alone, with concomitant or maintenance temozolomide or with both concomitant and maintenance temozolomide showed a significant prolongation of OS in patients receiving radiotherapy followed by 12 cycles of maintenance temozolomide and, thus, this approach should be considered standard of care; however, the role of concomitant temozolomide remains uncertain88. Indeed, updated data from CATNON indicate that concomitant temozolomide provides limited improvement to the overall favourable outcomes associated with maintenance chemotherapy and, more importantly, that only patients with IDH-mutant tumours derive benefit from chemotherapy (either as maintenance or concomitantly)89.

First-line therapy informs the choice of treatment in the recurrent disease setting (Fig. 2). Second surgery should be considered for all patients. For those with disease relapse after radiotherapy, re-irradiation after a minimum interval of ~12 months following the first course of radiotherapy is an option, although tumour size and patterns of recurrence limit the option of re-irradiation and the overall efficacy of this strategy remains uncertain in the absence of data from RCTs. Alkylating agent-based chemotherapy should be considered for patients who have not received previous chemotherapy and with disease progression after radiotherapy. Temozolomide and nitrosoureas are probably equally effective in this setting90,91. Adding bevacizumab to temozolomide prolongs neither PFS nor OS durations in patients with contrast-enhancing recurrent IDH-mutant gliomas without 1p/19q codeletion14.


  • The standard of care for IDH-mutant astrocytomas, WHO grade 2 requiring further treatment includes resection as feasible or biopsy followed by involved field radiotherapy and maintenance PCV polychemotherapy (RTOG 9802)75. C: II; L: B.

  • The standard of care for IDH-mutant astrocytomas, WHO grade 3 includes resection as feasible or biopsy followed by involved field radiotherapy and maintenance temozolomide (CATNON)88. C: II; L: B.

  • Patients with IDH-mutant and 1p/19q-codeleted oligodendrogliomas, WHO grade 2 requiring further treatment should be treated with radiotherapy followed by PCV polychemotherapy. C: III; L: B.

  • Patients with IDH-mutant and 1p/19q-codeleted oligodendrogliomas, WHO grade 3 should be treated with radiotherapy followed by PCV polychemotherapy (EORTC 26951, RTOG 9402)79,80. C: II; L: B.

  • Temozolomide chemotherapy is standard treatment at progression after surgery and radiotherapy for most patients with IDH-mutant gliomas, WHO grade 2 or 3. C: II; L: B.

IDH-wild-type glioblastoma, WHO grade 4

These tumours include histologic variants such as giant cell glioblastoma, gliosarcoma and epithelioid glioblastoma. Tumours formerly diagnosed as IDH-mutant glioblastoma are now referred to as IDH-mutant astrocytoma, WHO grade 4, and are managed either as IDH-wild-type glioblastoma or as IDH-mutant astrocytoma, WHO grade 3 (Table 2).

Surgery for glioblastoma should involve gross total resection whenever feasible46. A small RCT in patients aged >65 years at diagnosis of a WHO grade 3 or 4 glioma reported longer OS durations with resection versus biopsy92, but the relevance of this trial remains debatable owing to the limited sample size and KPS imbalances between treatment groups.

For decades, radiotherapy (60 Gy in 1.8–2 Gy fractions) has been the standard of care for glioblastoma, approximately doubling median OS durations50. Radiotherapy (50 Gy in 1.8 Gy fractions) improved OS relative to best supportive care in patients aged ≥70 years with a good KPS (≥70)51. Patients with unfavourable prognostic factors (defined by age and/or KPS) can be treated with hypofractionated radiotherapy (such as 40 Gy in 15 fractions), which has similar activity to irradiation with 60 Gy in 30 fractions54. Further hypofractionation to 5 × 5 Gy does not seem to compromise OS93 but is likely to cause neurocognitive adverse events if, in the future, elderly patients with glioblastoma live longer because of improved systemic treatment. Neither accelerated hyperfractionated or hypofractionated regimens nor brachytherapy, radiosurgery or a stereotactic radiotherapy boost are superior to standard radiotherapy regimens in terms of OS57. Concomitant radiotherapy and chemotherapy with temozolomide (75 mg/m2 daily throughout radiotherapy, including at weekends) plus six cycles of maintenance temozolomide (150–200 mg/m2, 5 out of 28 days) is the standard of care for adults with newly diagnosed glioblastoma who are in good general and neurological condition and are aged <70 years59. The addition of temozolomide to hypofractionated radiotherapy54 has also been shown to improve OS in patients aged ≥60 years94. The benefit from temozolomide is largely limited to patients with MGMT promoter-methylated glioblastoma94,95. The results of the NOA-08 (refs96,97) and Nordic trials98 led to MGMT promoter methylation testing becoming standard practice in many European countries for the management of elderly patients not considered eligible for combined modality treatment: patients with tumours lacking MGMT promoter methylation or of unknown MGMT promoter methylation status should be treated with hypofractionated radiotherapy alone whereas those with tumours with MGMT promoter methylation status should receive temozolomide alone (5 out of 28 days until disease progression or for 12 months)97. Until 2016, the broad consensus was that the results of all trials involving patients with tumours without MGMT promoter methylation showed no detriment from the omission of temozolomide99, challenging the view that this agent should be used in every patient regardless of MGMT promoter methylation status. This notion has become controversial again after a minor OS prolongation with radiotherapy plus temozolomide versus radiotherapy alone was observed in elderly patients with glioblastomas lacking MGMT promoter methylation94 and with the negative outcome of the CheckMate 498 trial100.

An open-label phase III trial of the addition of tumour-treating fields to maintenance temozolomide in patients with newly diagnosed glioblastoma revealed superior PFS and OS outcomes across all patient and tumour subgroups101, without relevant differences in QOL between arms102. However, questions have been raised regarding the mode of action, the study design without a sham control, the interpretation of data and the effect on health-related QOL in the general patient population103. Additionally, the feasibility and cost-effectiveness of tumour-treating fields as a standard of care for newly diagnosed glioblastoma remain highly controversial104. A focus on supportive and palliative care is appropriate for patients with large or multifocal lesions with a low KPS, notably if they are unable to provide consent for further therapy after biopsy74.

No benefit has been reported from increasing the dose of temozolomide in patients with newly diagnosed disease105 nor from extending the duration of chemotherapy beyond six cycles106. However, combining temozolomide with lomustine in the newly diagnosed setting might extend OS in patients with MGMT promoter-methylated glioblastoma107. This phase III trial involved a small cohort, did not show superior PFS for the combination and might deprive patients from lomustine, the standard of care at recurrence; thus, the use of this regimen appears to be largely restricted to some sites in German-speaking countries. The results of two phase III trials involving adults with glioblastoma demonstrated a prolongation of PFS (3–4 months) but not of OS when bevacizumab was added to temozolomide chemoradiotherapy108,109. A phase II trial involving a small cohort of elderly patients with MGMT promoter-unmethylated glioblastoma had similar results110; however, the clinical significance of such PFS gains is unclear because the reliability of assessing progression by neuroimaging can be questioned and because data from the RTOG 0825 trial raised concerns of early cognitive decline in patients treated with bevacizumab109. Bevacizumab has therefore not been approved for the treatment of newly diagnosed glioblastoma, with very few exceptions worldwide, but could be useful in patients with large tumours who are highly symptomatic and who might not otherwise tolerate radiotherapy. In the field of immunotherapy, negative phase III trials for OS include that of the EGFR-targeted vaccine rindopepimut in patients with EGFRvIII-positive glioblastoma111 and that of the immune checkpoint inhibitor nivolumab in patients with MGMT promoter unmethylated glioblastoma100.

Standard-of-care treatments for patients with recurrent glioblastoma are not well defined; treatment is selected on the basis of prior therapy, age, KPS, MGMT promoter methylation status and patterns of disease progression (Fig. 3). Second surgery is an option for ~20–30% of patients, commonly with symptomatic but circumscribed relapses diagnosed not earlier than 6 months after initial surgery. Second surgery earlier than 6 months after initial surgery increases the risk of unnecessary intervention on the basis of pseudoprogression and is unlikely to provide durable benefit if the initial surgery followed by radiotherapy did not provide tumour control for more than a few months. Second surgery can also be considered upon early progression in symptomatic patients who might not have had adequate initial surgery. This procedure might improve post-recurrence survival in patients who are candidates for gross total resection of enhancing tumour112.

Fig. 3: Clinical pathway for IDH-wild-type glioblastomas, WHO grade 4.
figure 3

KPS, Karnofsky performance status.

The efficacy of re-irradiation and the value of amino acid PET for target delineation remain debated. Radiation fractionation depends on tumour size. Larger lesions require smaller single fraction sizes to improve the safety and tolerability. Doses of conventional or near conventional fractionation have been tested as well as higher doses per fraction (5–6 Gy) using stereotactic hypofractionated radiotherapy to a total dose of 30–36 Gy or even radiosurgery with a single dose of 15–20 Gy, all with acceptable toxicity profiles113. The only RCT exploring bevacizumab plus radiotherapy versus bevacizumab alone reported improved PFS but not OS114.

The main systemic treatment options for patients with disease progression include nitrosoureas, temozolomide rechallenge, bevacizumab (depending on availability) or inclusion into a clinical trial. Lomustine (90–110 mg/m2) has never been shown to have superiority over another agent in an RCT60 but is increasingly considered as the most appropriate standard of care on the basis of its activity as the control arm of several RCTs65,115 and is also used in the AGILE trial116, with 6-month PFS rates of ~20%60. Similar results have been reported with alternative dosing schedules of temozolomide but activity is probably limited to patients with tumours with MGMT promoter methylation117,118. No data from RCTs support the view that dose-intensified schedules are superior to standard-dose temozolomide in patients with recurrent glioblastoma after a temozolomide-free interval.

Bevacizumab is not approved for patients with recurrent glioblastoma in the European Union, although it has been approved for this indication in other countries on the basis of objective response rates of ~30% in two uncontrolled phase II trials66,67. Bevacizumab has not been compared with placebo, and an effect on OS was not observed upon combination with lomustine as compared with lomustine alone65. To date, no active combination partner for bevacizumab to prolong OS has been identified. The main value of this agent in routine clinical practice is transient symptom control and the option for sparing treatment with steroids in symptomatic patients with large tumours.

In other studies of potential treatments for recurrent glioblastoma, nivolumab was not superior to bevacizumab119 and tumour-treating fields were not superior to physician’s choice of best treatment120. So far, only a limited role for targeted therapy in recurrent glioblastoma has been shown12. Approximately 50% of the rare epithelioid glioblastomas, an entity that remains controversial because of its similarity to anaplastic pleomorphic xanthoastrocytoma, harbour BRAFV600E mutations. Patients with such tumours might benefit from BRAF inhibitors, at least in the setting of disease recurrence121.


  • The standard of care for patients with IDH-wild-type glioblastoma aged <70 years and with a KPS >70 includes resection as feasible or biopsy followed by involved-field radiotherapy and concomitant radiotherapy and six cycles of maintenance temozolomide chemotherapy (EORTC 26981-NCIC CE.3)59. C: I; L: A.

  • Temozolomide might only be active in patients with MGMT promoter-methylated tumours whereas its activity in patients with MGMT promoter-unmethylated tumours is probably marginal95. C: II; L: B.

  • Elderly patients not considered candidates for temozolomide chemoradiotherapy should be treated on the basis of MGMT promoter methylation status (NOA-08, Nordic Trial) with radiotherapy (such as 15 × 2.66 Gy) or temozolomide (5 out of 28 days) alone96,98,97. C: II; L: B.

  • At recurrence, standards of care are less well defined. Surgery and radiotherapy might be considered. Nitrosourea regimens, temozolomide rechallenge and, with consideration of the country-specific label, bevacizumab are options of pharmacotherapy but an impact on OS remains unproven. When available, recruitment into appropriate clinical trials should be considered. C: II; L: B.

H3 K27M-mutant diffuse midline glioma, WHO grade 4

This tumour type includes the majority of brainstem, thalamic and spinal diffuse gliomas in children and adults. Surgical options are limited and benefits from treatment options beyond radiotherapy have not been established because these tumours are rare and have not been studied in dedicated trials. In these tumours, the MGMT promoter is usually unmethylated. The prognosis of patients with this tumour type is poor.

H3.3 G34-mutant diffuse hemispheric glioma, WHO grade 4

These tumours mostly occur in adolescents and young adults and the MGMT promoter is more often methylated than unmethylated122. These tumours were previously classified as IDH-wild-type glioblastomas and, thus, a reasonable treatment approach for such patients is chemoradiotherapy.

Discouraged treatments

Steroids should not be given to treat asymptomatic or minimally symptomatic oedema and should be tapered as soon as possible, considering their unfavourable safety profile upon long-term administration. Furthermore, steroid use has been shown to be a negative prognostic factor for OS in patients with glioblastoma from three separate large cohorts123 and might interfere with the efficacy of radiotherapy, chemotherapy and immunotherapy.

Furthermore, we advocate against the use of any treatment beyond confirmed progression on that same treatment, including bevacizumab124 and tumour-treating fields, because the clinical benefit of this practice has not been established. Several chemotherapy regimens commonly used to treat other tumour types, including irinotecan and platinum compounds, are known not to be active against gliomas and should therefore not be used in this setting.

Given the poor outcomes of many patients with diffuse gliomas, new treatment concepts emerge and vanish that have never been tested in appropriate RCTs and the use of which outside a clinical trial is discouraged. Examples include the cocktail of repurposed drugs referred to as CUSP9, cannabinoids, methadone, sulfasalazine and valproate (except for seizure control).


The revision of the WHO Classification of Tumors of the Central Nervous System1 has led to major changes in the way we routinely diagnose and treat patients with gliomas. The diagnosis and management plans should follow multidisciplinary tumour board recommendations throughout the course of disease. Multidisciplinary tumour board meetings are the fora for the discussion of whether treatments should be delivered locally or at a specialized centre and in inpatient or outpatient settings as well as to determine which neurorehabilitation measures would be useful. Local and national guidelines as well as EANO guidelines provide further guidance. Guidelines reflect knowledge and consensus at a given time; information on future updates will be posted on the EANO website. For many of the newly defined disease entities in the latest WHO classification, data on specific treatments and outcomes are not yet available; extrapolating data from clinical trials to these novel entities remains challenging. Well-designed, molecularly enriched RCTs are necessary to substantiate some of the treatment recommendations of the present guidelines.


  1. 1.

    Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W. K. (eds) World Health Organization Histological Classification of Tumors of the Central Nervous System (International Agency for Research on Cancer, 2016)

  2. 2.

    Brat, D. J. et al. cIMPACT-NOW update 3: recommended diagnostic criteria for ‘Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV’. Acta Neuropathol. 136, 805–810 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Brat, D. J. et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 139, 603–608 (2020).

    PubMed  Google Scholar 

  4. 4.

    Louis, D. N. et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 30, 844–856 (2020).

    PubMed  Google Scholar 

  5. 5.

    Weller, M. et al. European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18, e315–e329 (2017).

    PubMed  Google Scholar 

  6. 6.

    Brainin, M. et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2004. Eur. J. Neurol. 11, 577–581 (2004).

    CAS  PubMed  Google Scholar 

  7. 7.

    Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-Oncology 21 (Suppl. 5), v1–v100 (2019).

    PubMed  PubMed Central  Google Scholar 

  8. 8.

    Rice, T. et al. Understanding inherited genetic risk of adult glioma - a review. Neurooncol. Pract. 3, 10–16 (2016).

    PubMed  Google Scholar 

  9. 9.

    Posti, J. P. et al. Presenting symptoms of glioma in adults. Acta Neurol. Scand. 131, 88–93 (2015).

    CAS  PubMed  Google Scholar 

  10. 10.

    Rasmussen, B. K. et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the danish neuro-oncology registry. J. Neurooncol. 135, 571–579 (2017).

    PubMed  Google Scholar 

  11. 11.

    Peeters, M. C. M. et al. Prediagnostic symptoms and signs of adult glioma: the patients’ view. J. Neurooncol. 146, 293–301 (2020).

    CAS  PubMed  Google Scholar 

  12. 12.

    Pace, A. et al. Determining medical decision-making capacity in brain tumor patients: why and how? Neurooncol. Pract. (2020).

  13. 13.

    Nayak, L. et al. The neurologic assessment in neuro-oncology (NANO) scale: a tool to assess neurologic function for integration into the response assessment in neuro-oncology (RANO) criteria. Neuro-Oncology 19, 625–635 (2017).

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    van den Bent, M. J. et al. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncol. 19, 1170–1179 (2018).

    PubMed  Google Scholar 

  15. 15.

    Folstein, M. F., Folstein, S. E. & McHugh, P. R. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975).

    CAS  PubMed  Google Scholar 

  16. 16.

    Nasreddine, Z. S. et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695–699 (2005).

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Ellingson, B. M., Wen, P. Y. & Cloughesy, T. F. modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14, 307–320 (2017).

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Albert, N. L. et al. Response assessment in neuro-oncology working group and european association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 18, 1199–1208 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Le Rhun, E., Seoane, J., Salzet, M., Soffietti, R. & Weller, M. Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. Cancer Lett. 480, 24–28 (2020).

    PubMed  Google Scholar 

  20. 20.

    Roth, P. et al. Neurological and vascular complications of primary and secondary brain tumors: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann. Oncol. (2020).

  21. 21.

    Williams, M., Treasure, P., Greenberg, D., Brodbelt, A. & Collins, P. Surgeon volume and 30 day mortality for brain tumours in England. Br. J. Cancer 115, 1379–1382 (2016).

    PubMed  PubMed Central  Google Scholar 

  22. 22.

    Eigenbrod, S. et al. Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochir. 156, 1427–1440 (2014).

    PubMed  Google Scholar 

  23. 23.

    Hamisch, C. A. et al. Frame-based stereotactic biopsy of deep-seated and midline structures in 511 procedures: feasibility, risk profile, and diagnostic yield. Acta Neurochir. 161, 2065–2071 (2019).

    PubMed  Google Scholar 

  24. 24.

    Grasbon-Frodl, E. M. et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int. J. Cancer 121, 2458–2464 (2007).

    CAS  PubMed  Google Scholar 

  25. 25.

    Millesi, M. et al. Is intraoperative pathology needed if 5-aminolevulinic-acid-induced tissue fluorescence is found in stereotactic brain tumor biopsy? Neurosurgery 86, 366–373 (2020).

    PubMed  Google Scholar 

  26. 26.

    Shirahata, M. et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 136, 153–166 (2018).

    CAS  PubMed  Google Scholar 

  27. 27.

    Banan, R. et al. Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathol. 140, 569–581 (2020).

    CAS  PubMed  Google Scholar 

  28. 28.

    Reinhardt, A. et al. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathol. Commun. 7, 163 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Appay, R. et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology 21, 1519–1528 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Tesileanu, C. M. S. et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology 22, 515–523 (2020).

    CAS  PubMed  Google Scholar 

  31. 31.

    Reuss, D. E. et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 130, 407–417 (2015).

    CAS  PubMed  Google Scholar 

  32. 32.

    Wick, W. et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81, 1515–1522 (2013).

    CAS  PubMed  Google Scholar 

  33. 33.

    Bady, P., Delorenzi, M. & Hegi, M. E. Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors. J. Mol. Diagn. 18, 350–361 (2016).

    CAS  PubMed  Google Scholar 

  34. 34.

    Preusser, M. et al. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 18, 520–532 (2008).

    CAS  PubMed  Google Scholar 

  35. 35.

    Sahm, F. et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 131, 903–910 (2016).

    CAS  PubMed  Google Scholar 

  36. 36.

    Zacher, A. et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel. Brain Pathol. 27, 146–159 (2017).

    CAS  PubMed  Google Scholar 

  37. 37.

    Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469–474 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Ferguson, S. D. et al. Targetable gene fusions associate with the IDH wild-type astrocytic lineage in adult gliomas. J. Neuropathol. Exp. Neurol. 77, 437–442 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Stichel, D. et al. Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathol. 138, 827–835 (2019).

    CAS  PubMed  Google Scholar 

  40. 40.

    Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7, 392–401 (2006).

    CAS  PubMed  Google Scholar 

  41. 41.

    De Witt Hamer, P. C., Robles, S. G., Zwinderman, A. H., Duffau, H. & Berger, M. S. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J. Clin. Oncol. 30, 2559–2565 (2012).

    PubMed  Google Scholar 

  42. 42.

    Brennum, J., Maier, C. M., Almdal, K., Engelmann, C. M. & Gjerris, M. Primo non nocere or maximum survival in grade 2 gliomas? A medical ethical question. Acta Neurochir. 157, 155–164 (2015).

    PubMed  Google Scholar 

  43. 43.

    Gulati, S., Jakola, A. S., Nerland, U. S., Weber, C. & Solheim, O. The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg. 76, 572–579 (2011).

    PubMed  Google Scholar 

  44. 44.

    Bette, S. et al. Patterns and time dependence of unspecific enhancement in postoperative magnetic resonance imaging after glioblastoma resection. World Neurosurg. 90, 440–447 (2016).

    PubMed  Google Scholar 

  45. 45.

    Grabowski, M. M. et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J. Neurosurg. 121, 1115–1123 (2014).

    PubMed  Google Scholar 

  46. 46.

    Molinaro, A. M. et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol. (2020).

  47. 47.

    Wijnenga, M. M. J. et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology 20, 103–112 (2018).

    CAS  PubMed  Google Scholar 

  48. 48.

    Press, R. H. et al. Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification. Cancer 126, 3255–3264 (2020).

    PubMed  Google Scholar 

  49. 49.

    Beiko, J. et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology 16, 81–91 (2014).

    CAS  PubMed  Google Scholar 

  50. 50.

    Walker, M. D. et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49, 333–343 (1978).

    CAS  PubMed  Google Scholar 

  51. 51.

    Keime-Guibert, F. et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med. 356, 1527–1535 (2007).

    CAS  PubMed  Google Scholar 

  52. 52.

    Breen, W. G. et al. Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma. Neuro-Oncology 22, 830–837 (2020).

    PubMed  Google Scholar 

  53. 53.

    Khan, L. et al. External beam radiation dose escalation for high grade glioma. Cochrane Database Syst. Rev. 5, CD011475 (2020).

    PubMed  Google Scholar 

  54. 54.

    Roa, W. et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol. 22, 1583–1588 (2004).

    CAS  PubMed  Google Scholar 

  55. 55.

    Niyazi, M. et al. ESTRO-ACROP guideline ‘target delineation of glioblastomas’. Radiother. Oncol. 118, 35–42 (2016).

    PubMed  Google Scholar 

  56. 56.

    Harrabi, S. B. et al. Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlenther. Onkol. 192, 759–769 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Malouff, T. D., Peterson, J. L., Mahajan, A. & Trifiletti, D. M. Carbon ion radiotherapy in the treatment of gliomas: a review. J. Neurooncol. 145, 191–199 (2019).

    PubMed  Google Scholar 

  58. 58.

    Nachbichler, S. B. & Kreth, F.-W. Brachytherapy of intracranial gliomas. Prog. Neurol. Surg. 31, 72–86 (2018).

    PubMed  Google Scholar 

  59. 59.

    Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).

    CAS  PubMed  Google Scholar 

  60. 60.

    Weller, M. & Le Rhun, E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat. Rev. 87, 102029 (2020).

    CAS  PubMed  Google Scholar 

  61. 61.

    Brem, H. et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345, 1008–1012 (1995).

    CAS  PubMed  Google Scholar 

  62. 62.

    Westphal, M. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5, 79–88 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Wen, P. Y. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology (2020).

  64. 64.

    Touat, M. et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580, 517–523 (2020).

    CAS  PubMed  Google Scholar 

  65. 65.

    Wick, W. et al. Lomustine and bevacizumab in progressive glioblastoma. N. Engl. J. Med. 377, 1954–1963 (2017).

    CAS  PubMed  Google Scholar 

  66. 66.

    Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733–4740 (2009).

    CAS  PubMed  Google Scholar 

  67. 67.

    Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740–745 (2009).

    CAS  PubMed  Google Scholar 

  68. 68.

    Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963–1972 (2010).

    PubMed  Google Scholar 

  69. 69.

    van den Bent, M. J. et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 12, 583–593 (2011).

    PubMed  Google Scholar 

  70. 70.

    Radbruch, A. et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro-Oncology 17, 151–159 (2015).

    PubMed  Google Scholar 

  71. 71.

    Ellingson, B. M. et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology 17, 1188–1198 (2015).

    PubMed  PubMed Central  Google Scholar 

  72. 72.

    Gui, C., Lau, J. C., Kosteniuk, S. E., Lee, D. H. & Megyesi, J. F. Radiology reporting of low-grade glioma growth underestimates tumor expansion. Acta Neurochir. 161, 569–576 (2019).

    PubMed  Google Scholar 

  73. 73.

    Zikou, A. et al. Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol. Imaging 2018, 6828396 (2018).

    PubMed  PubMed Central  Google Scholar 

  74. 74.

    Pace, A. et al. European association for neuro-oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 18, e330–e340 (2017).

    PubMed  Google Scholar 

  75. 75.

    Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N. Engl. J. Med. 374, 1344–1355 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Wahl, M. et al. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro-Oncology 19, 242–251 (2017).

    CAS  PubMed  Google Scholar 

  77. 77.

    Rudà, R. et al. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. J. Neurooncol. 145, 115–123 (2019).

    PubMed  Google Scholar 

  78. 78.

    Wick, W. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 5874–5880 (2009).

    CAS  PubMed  Google Scholar 

  79. 79.

    Cairncross, G. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31, 337–343 (2013).

    CAS  PubMed  Google Scholar 

  80. 80.

    van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. 31, 344–350 (2013).

    PubMed  Google Scholar 

  81. 81.

    Habets, E. J. J. et al. Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. J. Neurooncol. 116, 161–168 (2014).

    PubMed  Google Scholar 

  82. 82.

    Wick, W. et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology 18, 1529–1537 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  83. 83.

    US National Library of Medicine. (2020).

  84. 84.

    Jakola, A. S. et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann. Oncol. 28, 1942–1948 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  85. 85.

    van den Bent, M. J. et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366, 985–990 (2005).

    PubMed  Google Scholar 

  86. 86.

    Baumert, B. G. et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 17, 1521–1532 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Bell, E. H. et al. Comprehensive genomic analysis in NRG oncology/RTOG 9802: A phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J. Clin. Oncol. 38, 3407–3417 (2020).

    CAS  PubMed  Google Scholar 

  88. 88.

    van den Bent, M. J. et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet (2017).

  89. 89.

    van den Bent, M. et al. ACTR-11. Second interim and 1st molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. Neuro-Oncology 21, vi14–vi14 (2019).

    PubMed Central  Google Scholar 

  90. 90.

    Yung, W. K. et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 2762–2771 (1999).

    CAS  PubMed  Google Scholar 

  91. 91.

    Brada, M. et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J. Clin. Oncol. 28, 4601–4608 (2010).

    CAS  PubMed  Google Scholar 

  92. 92.

    Vuorinen, V., Hinkka, S., Färkkilä, M. & Jääskeläinen, J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir. 145, 5–10 (2003).

    CAS  PubMed  Google Scholar 

  93. 93.

    Roa, W. et al. International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 33, 4145–4150 (2015).

    PubMed  Google Scholar 

  94. 94.

    Perry, J. R. et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N. Engl. J. Med. 376, 1027–1037 (2017).

    CAS  PubMed  Google Scholar 

  95. 95.

    Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).

    CAS  PubMed  Google Scholar 

  96. 96.

    Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 13, 707–715 (2012).

    CAS  PubMed  Google Scholar 

  97. 97.

    Wick, A. et al. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma. Neuro-Oncology (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  98. 98.

    Malmström, A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 13, 916–926 (2012).

    PubMed  Google Scholar 

  99. 99.

    Weller, M. Where does O6 -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma? Cancer 124, 1316–1318 (2018).

    PubMed  Google Scholar 

  100. 100.

    US National Library of Medicine. (2020).

  101. 101.

    Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306–2316 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  102. 102.

    Taphoorn, M. J. B. et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4, 495–504 (2018).

    PubMed  PubMed Central  Google Scholar 

  103. 103.

    Wick, W. TTFields: where does all the skepticism come from? Neuro-Oncology 18, 303–305 (2016).

    PubMed  PubMed Central  Google Scholar 

  104. 104.

    Bernard-Arnoux, F. et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro-Oncology 18, 1129–1136 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  105. 105.

    Gilbert, M. R. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J. Clin. Oncol. 31, 4085–4091 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  106. 106.

    Balana, C. et al. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01). Neuro-Oncology (2020).

  107. 107.

    Herrlinger, U. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393, 678–688 (2019).

    CAS  PubMed  Google Scholar 

  108. 108.

    Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709–722 (2014).

    CAS  PubMed  Google Scholar 

  109. 109.

    Gilbert, M. R., Sulman, E. P. & Mehta, M. P. Bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 2048–2049 (2014).

    CAS  PubMed  Google Scholar 

  110. 110.

    Wirsching, H.-G. et al. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann. Oncol. 29, 1423–1430 (2018).

    PubMed  Google Scholar 

  111. 111.

    Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).

    CAS  PubMed  Google Scholar 

  112. 112.

    Suchorska, B. et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology 18, 549–556 (2016).

    PubMed  PubMed Central  Google Scholar 

  113. 113.

    Ryu, S. et al. The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 118, 489–499 (2014).

    CAS  PubMed  Google Scholar 

  114. 114.

    Tsien, C. et al. ACTR-32. NRG ONCOLOGY RTOG 1205: randomized phase II trial of concurrent bevacizumab and re-irradiation vs. bevacizumab alone as treatment for recurrent glioblastoma. Neuro-Oncology 21, vi20–vi20 (2019).

    PubMed Central  Google Scholar 

  115. 115.

    Batchelor, T. T. et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28, 2817–2823 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  116. 116.

    Becker Buxton, M. et al. GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. J. Clin. Oncol. (2020).

  117. 117.

    Perry, J. R. et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 28, 2051–2057 (2010).

    CAS  PubMed  Google Scholar 

  118. 118.

    Weller, M. et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin. Cancer Res. 21, 2057–2064 (2015).

    CAS  PubMed  Google Scholar 

  119. 119.

    Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. (2020).

  120. 120.

    Stupp, R. et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192–2202 (2012).

    PubMed  Google Scholar 

  121. 121.

    Kaley, T. et al. BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J. Clin. Oncol. 36, 3477–3484 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  122. 122.

    Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425–437 (2012).

    CAS  PubMed  Google Scholar 

  123. 123.

    Pitter, K. L. et al. Corticosteroids compromise survival in glioblastoma. Brain 139, 1458–1471 (2016).

    PubMed  PubMed Central  Google Scholar 

  124. 124.

    Hovey, E. J. et al. Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. Neurooncol Pract. 4, 171–181 (2017).

    PubMed  PubMed Central  Google Scholar 

  125. 125.

    US National Library of Medicine. (2020).

Download references

Author information




M.W. wrote the first draft of the manuscript. All other authors reviewed the draft and approved the final version of the manuscript.

Corresponding author

Correspondence to Michael Weller.

Ethics declarations

Competing interests

M.W. reports grants and personal fees from Abbvie, Merck (EMD) and MSD, grants from Adastra, Dracen and Novocure, personal fees from Basilea, BMS, Celgene, Medac, Nerviano Medical Sciences, Orbus, Roche and Tocagen. M.vdB. reports personal fees from Abbvie, Agios, Bayer, Carthera, Genenta, Karyopharm and Nerviano Medical Sciences. M.Preusser reports grants and personal fees from Abbvie, Daiichi Sankyo, GlaxoSmithKline and MSD, grants from Böhringer Ingelheim, Bristol Myers Squibb, Novocure and Roche, and personal fees from AstraZeneca, Bayer, BMJ Journals, BMS, CMC Contrast, Gerson Lehrman Group, Lilly, Medahead, MedMedia, Mundipharma, Novartis, Roche, Sanofi and Tocagen. E.L.R. reports personal fees from Abbvie, Daiichy Sankyo and Tocagen. J.C.T. reports personal fees from BrainLab and Carthera. M.B. reports grants and personal fees from Novartis, grants from Siemens, and personal fees from B. Braun, Bayer, Boehringer Ingelheim, Grifols, Merck, Springer, Teva and Vascular Dynamics. C.B. reports personal fees from Celgene, Karyopharm, Lipopharma and Pharmamar, and other support from Abbvie. O.C. reports personal fees and travel support from Abbvie. M.E.H. reports funding from Bristol Myers Squibb and Novocure. A.S.J. reports personal fees from INOMED. M.Pl. reports non-financial support from Pfizer and Roche, personal fees and supply of reagents from Bayer, and personal fees from Affiris, Apogenix and Novartis. In addition, M.Pl has six patents licensed to Bayer (EP2753315B1, WO2018146010A1, WO2019101643A1, WO2019101647A1, WO2019101641A1 and WO2019101642A1), one patent issued (EP2800580B1) and three patents pending (US20180155403A1, US20180246118A1 and US20170254803A1). P.R. reports grants and personal fees from Novocure and personal fees from Bristol Myers Squibb, Debiopharm, Medac, Merck, MSD, QED and Roche. S.S. reports personal fees from Hox Therapeutics and Tocagen and personal fees and support of reagents from Abbvie. M.S. reports other support from GE Healthcare and Parexel. A.vD. receives royalties for the diagnostic use of IDH1 R132H mutant-specific antibody H09; all terms are being managed by the German Cancer Research Center in accordance with its conflict of interest policies. R.S. reports personal fees from AstraZeneca, EISAI, Merck and Puma Biotechnologies. G.R. reports personal fees from Abbvie. G.M., L.D., P.F., R.R., M.J.B.T., M.W. and W.W. declare no competing interests.

Additional information


The preparation of these evidence- based guidelines was not funded. The members of the task force did not receive compensation for their participation.

Peer review information

Nature Reviews Clinical Oncology thanks E.A. Chiocca, M. Prados, N. Sanai and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Related links

European Association of Neuro-Oncology (EANO):

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Weller, M., van den Bent, M., Preusser, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18, 170–186 (2021).

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing